1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Sandoz Launches Biosimilar Pyzchiva Across Europe, to Treat Chronic Inflammatory Diseases

26 Jul 2024
Admin
News Article

Sandoz Launches Biosimilar Pyzchiva Across Europe, to Treat Chronic Inflammatory Diseases

Overview

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab) across Europe, starting today. Pyzchiva, developed and registered by Samsung Bioepis, is the first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including the 130mg vial initiation dose for Crohn’s disease.

Post Launch Benefits

The launch strengthens our well-established immunology portfolio in Europe and leverages our existing footprint, with five biosimilars now marketed in this therapeutic area.
Pyzchiva is a key biosimilar driver, adding value and contributing to the company’s mid-term growth strategy.

Words from the President: Sandoz

Rebecca Guntern, president Europe, Sandoz, said: “Timely and expanded access to safe, effective and affordable medicines can improve quality of life for millions of people living with chronic inflammatory diseases. Our goal is to make potentially life-changing medicines accessible to patients across Europe. Pyzchiva is one of the first ustekinumab biosimilars in Europe, which marks a significant milestone on that road.”

Pyzchiva: Indications

Pyzchiva is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and paediatric plaque psoriasis for patients six years and older weighing over 60 kg.

Prevalence of Psoriasis

Europe has the highest prevalence of psoriasis worldwide, affecting an estimated 6.4 million people and significantly impacting patients’ quality of life. Plaque psoriasis is the most common form of psoriasis, affecting 85% to 90% of patients with psoriasis.

Agreement for Biosimilar

Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023.
Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva in the US, Canada, the European Economic Area, Switzerland, and the UK.
Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing, and supply.

Pyzchiva: As a Biosimilar

Pyzchiva (ustekinumab) has been developed as a biosimilar with equivalent efficacy and comparable safety to the reference medicine Stelara, a human monoclonal antibody against interleukin (IL)-12/23.
Pyzchiva is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and paediatric plaque psoriasis for patients six years and older weighing over 60 kg.
Pyzchiva is available as a 130 mg concentrate in a vial for solution for infusion, additionally, a 90 mg and a 45 mg concentrate solution for injection in a pre-filled syringe.